Journal
BLOOD
Volume 131, Issue 24, Pages 2651-2660Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-11-785865
Keywords
-
Categories
Funding
- Australian National Health and Medical Research Council [APP1031728]
- National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases [R37 AI34495]
- National Heart, Lung, NIH Blood Institute [R01 HL56067, HL11879]
- NIH National Cancer Institute [P01 CA142106, P01 CA065493]
- NATIONAL CANCER INSTITUTE [P01CA142106, P01CA065493] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL118979, R01HL056067] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI056299, R37AI034495] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Current approaches to prevent and treat graft-versus-host disease (GVHD) after stem cell transplantation rely principally on pharmacological immune suppression. Such approaches are limited by drug toxicity, nonspecific immune suppression, and a requirement for long-term therapy. Our increased understanding of the regulatory cells and molecular pathways involved in limiting pathogenic immune responses opens the opportunity for the use of these cell subsets to prevent and/or GVHD. The theoretical advantages of this approach is permanency of effect, potential for facilitating tissue repair, and induction of tolerance that obviates a need for ongoing drug therapy. To date, a number of potential cell subsets have been identified, including FoxP3(+) regulatory T (Treg) and FoxP3(neg)IL-10(+) (FoxP3-negative) regulatory T (Tr1), natural killer (NK) and natural killer T (NKT) cells, innate lymphoid cells, and various myeloid suppressor populations of hematopoietic (eg, myeloid derived suppressor cells) and stromal origin (eg, mesenchymal stem cells). Despite initial technical challenges relating to large-scale selection and expansion, these regulatory lineages are now undergoing early phase clinical testing. To date, Treg therapies have shown promising results in preventing clinical GVHD when infused early after transplant. Results from ongoing studies over the next 5 years will delineate the most appropriate cell lineage, source (donor, host, third party), timing, and potential exogenous cytokine support needed to achieve the goal of clinical transplant tolerance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available